Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
2008
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
2008
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
2003
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases
2006
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Cancer Statistics, 2006
2006 Standout
Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer
2008
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
2014 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study
2014
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization
2007
Oesophageal carcinoma
2013 Standout
Nasopharyngeal carcinoma
2015 Standout
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration
2010
Malignant Gliomas in Adults
2008 Standout
Oncogenes and tumor angiogenesis
2004
A new PET tracer specific for vascular endothelial growth factor receptor 2
2007
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
2005
tBuLi‐Mediated One‐Pot Direct Highly Selective Cross‐Coupling of Two Distinct Aryl Bromides
2015 StandoutNobel
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Photodynamic therapy: Combined modality approaches targeting the tumor microenvironment
2006
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models
2004
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model
2005
Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
2004
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma
2004
Modes of resistance to anti-angiogenic therapy
2008 Standout
Strategies to improve radiotherapy with targeted drugs
2011
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Nickel‐Catalyzed Cross‐Coupling of Organolithium Reagents with (Hetero)Aryl Electrophiles
2015 StandoutNobel
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
2009
3d Transition Metals for C–H Activation
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor–Extracellular Signal-Regulated Kinase Pathway
2004
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
2007
The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
2003
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
2004
Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab
2007
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation
2005
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
2006 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
2005
Cancer Stem Cells in Radiation Resistance
2007
Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer
2005
Cancer Genome Landscapes
2013 StandoutScience
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Applications of Fluorine in Medicinal Chemistry
2015 Standout
CF2H, a Hydrogen Bond Donor
2017 Standout
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
2007
Works of Roberta Caputo being referenced
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
2003
Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer
2004
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
2003
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
2004
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
2002